Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 May 15;9(5):e96017.
doi: 10.1371/journal.pone.0096017. eCollection 2014.

Safety of daily co-trimoxazole in pregnancy in an area of changing malaria epidemiology: a phase 3b randomized controlled clinical trial

Christine Manyando  1 , Eric M Njunju  1 , David Mwakazanga  2 , Gershom Chongwe  2 , Rhoda Mkandawire  3 , Davies Champo  2 , Modest Mulenga  2 , Maaike De Crop  4 , Yves Claeys  4 , Raffaella M Ravinetto  5 , Chantal van Overmeir  4 , Umberto D' Alessandro  6 , Jean-Pierre Van Geertruyden  7
Affiliations
Clinical Trial

Safety of daily co-trimoxazole in pregnancy in an area of changing malaria epidemiology: a phase 3b randomized controlled clinical trial

Christine Manyando et al. PLoS One. .

Abstract

Introduction: Antibiotic therapy during pregnancy may be beneficial and impacts positively on the reduction of adverse pregnancy outcomes. No studies have been done so far on the effects of daily Co-trimoxazole (CTX) prophylaxis on birth outcomes. A phase 3b randomized trial was conducted to establish that daily CTX in pregnancy is not inferior to SP intermittent preventive treatment (IPT) in reducing placental malaria; preventing peripheral parasitaemia; preventing perinatal mortality and also improving birth weight. To establish its safety on the offspring by measuring the gestational age and birth weight at delivery, and compare the safety and efficacy profile of CTX to that of SP.

Methods: Pregnant women (HIV infected and uninfected) attending antenatal clinic were randomized to receive either daily CTX or sulfadoxine-pyrimethamine as per routine IPT. Safety was assessed using standard and pregnancy specific measurements. Women were followed up monthly until delivery and then with their offspring up to six weeks after delivery.

Results: Data from 346 pregnant women (CTX = 190; SP = 156) and 311 newborns (CTX = 166 and SP = 145) showed that preterm deliveries (CTX 3.6%; SP 3.0%); still births (CTX 3.0%; SP 2.1%), neonatal deaths (CTX 0%; SP 1.4%), and spontaneous abortions (CTX 0.6%; SP 0%) were similar between study arms. The low birth weight rates were 9% for CTX and 13% for SP. There were no birth defects reported. Both drug exposure groups had full term deliveries with similar birth weights (mean of 3.1 Kg). The incidence and severity of AEs in the two groups were comparable.

Conclusion: Exposure to daily CTX in pregnancy may not be associated with particular safety risks in terms of birth outcomes such as preterm deliveries, still births, neonatal deaths and spontaneous abortions compared to SP. However, more data are required on CTX use in pregnant women both among HIV infected and un-infected individuals.

Trial registration: Clinicaltrials.gov NCT00711906.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Study Design.
Figure 2
Figure 2. Trial Profile.
See this image and copyright information in PMC

References

    1. WHO (2012) World Malaria Report.
    1. WHO (2006) Roll Back Malaria Partnership.
    1. Shulman CE, Dorman EK (2003) Reducing childhood mortality in poor countries - importance and prevention of malaria in pregnancy. Trans R Soc Trop Med Hyg 97: 30–35. - PubMed
    1. Whitty CJ, Edmonds S, Mutabingwa TK (2005) Malaria in pregnancy. BJOG 112: 1189–1195. - PubMed
    1. WHO: Assessment of the safety of artemisinin compounds in pregnancy [http://www.who.int/entity/malaria/publications/atoz/9789241596114/en/ind...].Accessed 2014 April 15.

Publication types

MeSH terms

Substances

Associated data